AbbVie Oy

Lähdeluettelot ja muu oheismateriaali

Kohonneen verenpaineen lääkehoito - tiedettä ja taidetta 4/2004

Ilkka Kantola


  1. Kastarinen M. Community control of hypertension. Kuopion yliopiston julkaisuja D. Lääketiede 280, 2002, 132.
  2. Meriranta P, Tikkanen I, Kumpusalo E ja työryhmä. Verenpainepotilas terveyskeskuksessa: hoitotulokset paranemassa. Suom Lääkäril 2004; 59: 3253-8.
  3. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br Med Bull 1994; 50: 272-98.
  4. Blood Pressure Lowering Treatment Trialists´ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
  5. Dahlöf B, Devereux Rb, Kjeldsen SE ym. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): arandomised trial against atenolol. Lancet 2002; 359: 995-1003.
  6. Lithell H, Hansson L, Skoog I ym. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-86.
  7. Julius S, Kjeldsen SE, Weber M ym. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004; 363: 2022-31.
  8. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-8.
  9. Verdecchia P, Reboldi G, Angeli F ym. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963–9.
  10. Sever PS, Dahlöf B, Poulter NR ym. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering ARM (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
  11. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Brit Med J 1995; 311: 293-5.
  12. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 1-11.
  13. Mar J, Rodriguez-Artalejo F. Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J Hypertens 2001; 19: 149-55
  14. Kyngäs H, Lahdenperä T. Compliance of patients with hypertension and associated factors. J Adv Nursing 1999; 29: 832-9.
  15. Bailey BJ, Carney SL, Giles AH ym. Hypertension treatment compliance: what do patients want to know about their medications? Prog Cardiovasc Nurs 1997; 12: 23-8.
  16. Strippoli GF, Craig M, Decks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004; 329: 828.
  17. Klingbeil AU, Schneider M, Martus P ym. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-6.
  18. Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. Int J Clin Pract 2004; 139 (suppl): 26-32.
  19. Whelton A, White WB, Bello AE, Puma JA, Fort JG: SUCCESS-VII investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959-63.

Työterveyslääkäriyhdistyksen kautta tavoitat laajalti työterveyslääkäreitä ja työterveyshuollon palveluntuottajia ympäri Suomen.